Adachi Y, Yoshizumi A, Ikarashi T, Takayanagi M, Takano M, Onoue Y, Kayahara M, Adachi Y, Matsuno M, Murakami G
Department of Pediatrics, Toyama Medical & Pharmaceutical University.
Arerugi. 1992 Nov;41(11):1584-90.
The aim of this study was to evaluate the efficacy of continuous isoproterenol inhalation therapy for severe asthma attacks in younger children, compared with its efficacy in older children. We used l-body isoproterenol (Proternol L) in 31 children with 42 episodes of severe attacks. They were divided into two group according to age: 20 cases under 6 years old (Group A), and 22 cases over 7 years old (Group B). All of the patients except for one in Group B, eventually improved with this therapy. Wood's clinical scores for Group A were significantly higher than those for group B (p < 0.01). In 22 cases whose scores were 5-6, their SpO2 values at the onset of this therapy were 90.8 +/- 3.17 in group A and 92.4 +/- 3.82% in group B. The improvement time of group A (13.6 +/- 16.2 hours) was significantly longer than that of group B (2.5 +/- 5.66, p < 0.01). The nebulized isoproternol doses for group A were 0.47 +/- 0.168 and for group B 0.26 +/- 0.096 mg/kg/saline 500 ml. The dose for group A was significantly higher than that for group B (p < 0.01). We concluded that continuous isoproterenol inhalation therapy was effective even in younger children. But the degree of efficacy was slightly lower in younger children, although they inhaled higher doses of isoproterenal than older children.
本研究的目的是评估持续异丙肾上腺素吸入疗法对年幼儿童重度哮喘发作的疗效，并与年长儿童进行疗效比较。我们对31例儿童的42次重度哮喘发作使用了1-体异丙肾上腺素（Proternol L）。根据年龄将他们分为两组：6岁以下20例（A组），7岁以上22例（B组）。除B组1例患者外，所有患者最终均通过该疗法得到改善。A组的伍德临床评分显著高于B组（p<0.01）。在22例评分为5-6分的患者中，该疗法开始时A组的SpO2值为90.8±3.17，B组为92.4±3.82%。A组的改善时间（13.6±16.2小时）显著长于B组（2.5±5.66，p<0.01）。A组雾化异丙肾上腺素剂量为0.47±0.168，B组为0.26±0.096mg/kg/500ml生理盐水。A组剂量显著高于B组（p<0.01）。我们得出结论，持续异丙肾上腺素吸入疗法即使在年幼儿童中也是有效的。但年幼儿童的疗效程度略低，尽管他们吸入的异丙肾上腺素剂量高于年长儿童。
